zzlangerhans’ Activity

Fri Jul 31

Caps Pick

zzlangerhans made a pick in CAPS. 3:35 PM

ARCA Biopharma, Inc. (ABIO) will Outperform the S&P 500

CAPS Outperform Pitch

zzlangerhans wrote about ESPERION THERAPEUTICS INC (ESPR) . 2:59 PM

ESPR Outperform

I'm way out of my depth with Esperion. They've clearly got an active drug in ETC-1002 with a great shot at strong phase III data and FDA approval. The question at this point is whether the commercial potential of ETC-1002 justifies the 1.8B valuation [more]

Thu Jul 30

CAPS Outperform Pitch

zzlangerhans wrote about Immunomedics, Inc. (IMMU) . 10:42 PM

IMMU Outperform

Lately my CAPS score and my real life accounts have been taking a drubbing as some of my long-term favorite stocks have taken a drubbing while a number of my most overvalued shorts have become twice as overvalued. One of the most painful aspects of [more]

Caps Pick

zzlangerhans made a pick in CAPS. 2:04 PM

Immunomedics, Inc. (IMMU) will Outperform the S&P 500

Mon Jul 27

CAPS Outperform Pitch

zzlangerhans wrote about Sunesis Pharmaceuticals, Inc. (SNSS) . 12:00 AM

SNSS Outperform

One of the most frustrating things about the biopharma sector is that logic is often completely insufficient as a basis for a profitable trade. Despite applying logic to my analysis of Sunesis and being completely correct about the outcome of every [more]

Fri Jul 24

Caps Pick

zzlangerhans made a pick in CAPS. 2:29 PM

ESPERION THERAPEUTICS INC (ESPR) will Outperform the S&P 500

Caps Pick

zzlangerhans made a pick in CAPS. 10:51 AM

Sunesis Pharmaceuticals, Inc. (SNSS) will Outperform the S&P 500

Thu Jul 23

CAPS Outperform Pitch

zzlangerhans wrote about XOMA Limited (XOMA) . 9:35 PM

XOMA Outperform

When I dropped my red thumb on Xoma years ago, I didn't know what Baker Brothers was. I just saw the company as a perma-disappointer experiencing an inexplicable and temporary rebound before eventually resuming their downward spiral to bankruptcy. [more]

Caps Pick

zzlangerhans made a pick in CAPS. 3:39 PM

XOMA Limited (XOMA) will Outperform the S&P 500

CAPS Underperform Pitch

zzlangerhans wrote about Synthetic Biologics, Inc. (SYN) . 12:39 PM

SYN Underperform

Synthetic Biologics has done vastly better than I ever imagined when I green thumbed them last year, but I'm going to bet the run is out of gas. MRI topline data from the phase II trial of Trimesta in MS has never materialized despite being promised [more]

CAPS Outperform Pitch

zzlangerhans wrote about AQUINOX PHARMACEUT (AQXP) . 11:45 AM

AQXP Outperform

Aquinox was looking pretty cheap before delivering the topline data from the LEADERSHIP and FLAGSHIP phase II trials of SHIP-1 activator AQX-1125 in interstitial cystitis and COPD. As it turned out, Aquinox wasn't an overlooked gem but an ignored [more]

Tue Jul 21

Caps Pick

zzlangerhans made a pick in CAPS. 11:58 AM

Synthetic Biologics, Inc. (SYN) will Underperform the S&P 500

Mon Jul 20

Caps Pick

zzlangerhans made a pick in CAPS. 12:30 PM

AQUINOX PHARMACEUT (AQXP) will Outperform the S&P 500

Fri Jul 17

CAPS Outperform Pitch

zzlangerhans wrote about NEPHROGENEX INC COM USD0.001 (NRX) . 12:03 PM

NRX Outperform

Nephrogenex is another belated addition to my database as it slides back towards all time lows following the latest dilutive financing. The only time I ever looked at this stock was after the remarkable 300% pop last New Year's Eve on a PR for a [more]

CAPS Outperform Pitch Reply

zzlangerhans commented on zzlangerhans's pitch for AQXP. 11:39 AM

The main value I see is 34M cash vs 19M market cap and still one potential positive catalyst in early 2016. The problem is, sometimes these cash plays with a string of failures just keep dropping forever (KaloBios).

Caps Pick

zzlangerhans made a pick in CAPS. 10:01 AM

NEPHROGENEX INC COM USD0.001 (NRX) will Outperform the S&P 500

Wed Jul 15

CAPS Underperform Pitch

zzlangerhans wrote about Curis, Inc. (CRIS) . 9:53 PM

CRIS Underperform

I could be wrong, but Curis' legacy pipeline doesn't seem to be going anywhere. Debiopharm ducked out of the partnership and the newly renamed CUDC-305 hasn't been lined up for any new trials. Likewise, the clinical hold on CUDC-427 has been lifted [more]

CAPS Underperform Pitch

zzlangerhans wrote about PTC Therapeutics, Inc. (PTCT) . 8:57 PM

PTCT Underperform

I haven't had much luck with my trading decisions over the last couple of weeks, but one good move was to cover the zzporte short of PTC Therapeutics for a small gain close to recent lows. The stock has roared back since the market stabilized capped [more]

Caps Pick

zzlangerhans made a pick in CAPS. 9:56 AM

Curis, Inc. (CRIS) will Underperform the S&P 500

Caps Pick

zzlangerhans made a pick in CAPS. 9:38 AM

PTC Therapeutics, Inc. (PTCT) will Underperform the S&P 500
Show More Activity ...

CAPS Stats & Trivia

CAPS Player Rating 99.69
Player Rank 236 out of 75193
Score 5545.49
Score Change Today +228.50
Accuracy 82.37%
Active Picks 170
Total Picks 2110
Best Pick MDVN (+1233.17)
Worst Pick PCYC.DL (-2886.09)
Average Score per Pick 2.63
Charms Earned 15
Highest Rated Favorite usubanas
Go to zzlangerhans’ CAPS page

Boards Stats & Trivia

Board Posts 0
Recs Received 0
People who have rec'd these posts 0
Recs to Posts Ratio (last 30 days) N/A
Threads Started 0
Threads Started Percentage 0.00 %
Most Frequent Board N/A
Very First Post N/A
Percentage of Posts Rec'd 100.00 %
Show zzlangerhans’ 10 Latest Posts